said its subsidiary hVivo has signed a deal with a major pharmaceutical client to manufacture a virus for use in human challenge studies.
Manufacturing has already begun, and the work is expected to be completed by the end of the third quarter.
Congrats Cathal.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más: